Cargando…
Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)
Epidermal growth factor receptor 1 (EGFR-1) overexpression is usually described as linked with a worse prognosis in a variety of tumours of epithelial origin. However, its role in ovarian cancer is still controversial. The aim of the present study was to analyse the prognostic impact of EGFR-1 in a...
Autores principales: | Elie, C, Geay, J F, Morcos, M, Le Tourneau, A, Girre, V, Broët, P, Marmey, B, Chauvenet, L, Audouin, J, Pujade-Lauraine, E, Camilleri-Broët, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409858/ https://www.ncbi.nlm.nih.gov/pubmed/15226774 http://dx.doi.org/10.1038/sj.bjc.6601961 |
Ejemplares similares
-
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
por: Tuefferd, Marianne, et al.
Publicado: (2007) -
CXCL12 expression by healthy and malignant ovarian epithelial cells
por: Machelon, Véronique, et al.
Publicado: (2011) -
Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2007) -
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009) -
Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study
por: Falandry, Claire, et al.
Publicado: (2015)